Cellular Dynamics, Roche, Acea Partner on Cardiotoxic Prediction Research | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche said today that it has partnered with Cellular Dyanmics and Acea Biosciences on technologies for the early and accurate prediction of cardiotoxic side effects in the drug discovery process.

The alliance will combine Cellular Dynamics' induced pluripotent stem cell-derived heart cells, called iCell Cardiomyocytes, with Roche's xCelligence RTCA System, a label-free cell analysis system which was co-developed by Acea.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.